ArticleBrain, behavior, & immunity - health2026
No excess risk of death or multimorbidity following hemorrhagic stroke after mRNA vaccination compared with historical cases: a population-based cohort study.
Article in Brain, behavior, & immunity - health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: While the association between hemorrhagic stroke and prior COVID-19 mRNA vaccination remains inconclusive, an examination of its prognosis may generate evidence on the potential causality of this relationship. If a causal link does exist, transient vaccine-related mechanisms (e.g., thrombocytopenia) might lead to a more favorable prognosis than naturally acquired cases. Aims: This study aimed to compare the prognosis of postvaccination hemorrhagic stroke and historical conventional cases with the same clinical diagnoses. Methods: A retrospective cohort study was conducted using a territory-wide electronic public healthcare database in Hong Kong, linked with population-based vaccination records. Since the roll-out of mRNA Vaccines (BNT162b2), patients aged 18 years or older hospitalized with hemorrhagic stroke within 28 days after mRNA vaccination were compared with conventional hemorrhagic stroke recorded between 2016 and 2017. The two-year follow-up period began from the diagnosis of hemorrhagic stroke. All-cause mortality and multimorbidity were examined using Cox proportional hazards models, with 95% confidence intervals (95%CIs) derived from bootstrap resampling (1000 iterations). Results: A total of 2578 patients were included for analysis: 110 in the postvaccination group and 2468 in the conventional group. Over the two-year follow-up period, all-cause death occurred in 27.27% (30/110) of the postvaccination group versus 29.78% (735/2468) in the conventional group. Multimorbidity was observed in 63.64% (70/110) of postvaccination cases and 73.14% (1805/2468) of conventional cases, respectively. Adjusted analyses showed no significant differences in all-cause mortality (adjusted Hazard Ratio [aHR] = 0.93, 95%CI:0.64-1.28) or multimorbidity risk (aHR = 0.85, 95%CI:0.66-1.05) between the two groups. Conclusion: Hemorrhagic stroke following mRNA vaccination had a similar long-term prognosis with conventional cases. These findings may suggest that most post-vaccination hemorrhagic strokes are coincidental rather than vaccine-induced and do not confer a different prognosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.